In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Clayton Culp, Hee Kee Kim and Salahadin Abdi Published 2 February 2021 | https://doi.org/10.3389/fphar.2020.599721 Abstract Ketamine, an N-methyl-D-aspartate receptor antagonist, is widely known as a dissociative anesthetic and phencyclidine derivative. Due to an undesirable adverse event profile when used as an anesthetic it had widely fallen out of human use in favor of more modern …
Ketamine Use for Cancer and Chronic Pain Management Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Jack Williams Shteamer, Mayson Augustus Callaway, Parth Patel & Vinita Singh Published Online 15 Oct 2019 | https://doi.org/10.2217/pmt-2019-0032 Abstract The effectiveness of ketamine in treating chronic neuropathic pain, however, remains a debated issue. A recent meta-analysis of double blind randomized controlled trials (DB-RCT) utilizing ketamine for chronic neuropathic pain revealed mixed results. Six studies were …
How effective is ketamine in the management of chronic neuropathic pain? Read More »
Yasushi Motoyama, Yoshitetsu Oshiro, Yumiko Takao, Hitoaki Sato, Norihiko Obata, Shinichiro Izuta, Satoshi Mizobuchi & Shigeyuki Kan Published 9 September 2019 | https://doi.org/10.1038/s41598-019-49360-1 Abstract Ketamine has been used to treat chronic pain; however, it is still unknown as to what types of chronic pain is ketamine effective against. To identify the effect of administration of …
Orhurhu, Vwaire MD, MPH; Orhurhu, Mariam Salisu MD, MPH; Bhatia, Anuj MD, FRCPC; Cohen, Steven P. MD 13 March 2019 | doi: 10.1213/ANE.0000000000004185 Abstract BACKGROUND: IV ketamine is widely used to treat patients with chronic pain, yet the long-term impact remains uncertain. We synthesized evidence from randomized control trials to investigate the effectiveness of IV …
Steven P. Cohen, MD; Anuj Bhatia, MBBS, MD; Asokumar Buvanendran, MD; Eric S. Schwenk, MD; Ajay D. Wasan, MD, MSc; Robert W. Hurley, MD, PhD; Eugene R. Viscusi, MD; Samer Narouze, MD, PhD; Fred N. Davis, MD; Elspeth C. Ritchie, MD, MPH; Timothy R. Lubenow, MD; and William M. Hooten, MD Published 1 July 2018 …
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain Read More »
Complex Regional Pain Syndrome Type 1 (CRPS-1) responds poorly to standard pain treatment. We evaluated if the N-methyl-D-aspartate receptor antagonist S(+)-ketamine improves pain in CRPS-1 patients.
This randomized double-blind placebo controlled trial was designed to evaluate the effectiveness of intravenous ketamine in the treatment of CRPS.